

Radiotheranostic agent development within reach



Radiomolecular Precision Oncology

RPO Group is a radiotheranostic CRO located in the heart of Western Europe, the global epicentre of radiomolecular precision oncology. This collaborative alliance of experts including Prof Dr Richard P Baum and Dr Hugo M L Jansen unites their respective specialities into a flexible, tailor-made approach.

Services


- → Clinical Study Management
- → Radiomolecular Image Handling & Analysis
- → Scientific & Medical Consultancy Services
- Medical Writing
- Molecule Mapping
- → Hospital & Site Network
- → Safety & Advisory Board
- → Legal Representation for non-EU Companies


The Rise of Radiotheranostics in Clinical Management

The current radiotheranostic revolution - primed for a rapid expansion in the coming years - is profoundly changing the multidisciplinary care of (metastatic) cancer patients, and may soon be among the most important pillars in clinical management. For Good.

At RPO Group, we enhance the development of radiotheranostics, focusing on surpassing traditional treatments in efficacy and safety. With a high failure rate of over 95% in clinical trials due to safety and efficacy issues, our use of advanced imaging technologies like SPECT-CT, PET-CT, and PET-MRI is key. We precisely identify suitable cancer patients for targeted therapies, leveraging radiotheranostics' unique ability to switch between diagnostic and therapeutic modes within the same molecular structure. This strategy aims to increase the effectiveness of clinical trials and lead the way to safer, more focused cancer treatments.







Get in touch

Do you have questions or requests? Is there anything you'd like to share? Or would you like to work with us? Don't hesitate to get in touch.

info@rpo-group.com +32 479 83 87 10 www.rpo-group.com



Molecule mapping.
We focus on the 360°
profiling of theranostic compounds.



Research. We offer the operational capacity for clinical research in Europe, APAC, and the USA.



Assessment. We take a critical look at the safety and efficacy of the therapeutic process.



Collaboration.
We work with leading clinical experts in the field of (radio)theranostic medicine.



Analysis. We interpret PET-CT and PET-MRI scans of patients using innovative radiolabeled molecules.



Clinical study advice. We design clinical studies for theranostic treatment.

